Replimune Group (NASDAQ:REPL) Upgraded at Wedbush

Wedbush upgraded shares of Replimune Group (NASDAQ:REPL) from a neutral rating to an outperform rating in a report released on Monday morning, MarketBeat.com reports. Wedbush currently has $18.00 target price on the stock, up from their prior target price of $4.00. Wedbush also issued estimates for Replimune Group’s FY2027 earnings at ($1.51) EPS, FY2028 earnings at ($0.68) EPS, FY2029 earnings at ($0.03) EPS and FY2030 earnings at $0.44 EPS.

Several other equities analysts have also recently weighed in on the stock. Piper Sandler cut shares of Replimune Group from an “overweight” rating to a “neutral” rating and set a $3.00 target price for the company. in a research note on Tuesday, July 22nd. Jefferies Financial Group cut their target price on shares of Replimune Group from $31.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, July 22nd. BMO Capital Markets cut shares of Replimune Group from an “outperform” rating to an “underperform” rating and cut their target price for the company from $27.00 to $2.00 in a research note on Wednesday, July 23rd. JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of Replimune Group in a research note on Friday, September 19th. Finally, Leerink Partnrs cut shares of Replimune Group from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $11.00.

Replimune Group Stock Up 2.5%

Shares of REPL stock opened at $8.30 on Monday. The company has a market capitalization of $647.90 million, a price-to-earnings ratio of -2.56 and a beta of 0.42. Replimune Group has a one year low of $2.68 and a one year high of $17.00. The company’s fifty day moving average price is $5.23 and its 200-day moving average price is $7.29. The company has a debt-to-equity ratio of 0.21, a current ratio of 6.94 and a quick ratio of 6.94.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.12). Sell-side analysts expect that Replimune Group will post -2.97 EPS for the current fiscal year.

Insider Activity at Replimune Group

In other Replimune Group news, CFO Emily Luisa Hill sold 9,154 shares of Replimune Group stock in a transaction on Friday, August 15th. The shares were sold at an average price of $5.37, for a total value of $49,156.98. Following the completion of the transaction, the chief financial officer directly owned 134,368 shares of the company’s stock, valued at $721,556.16. This trade represents a 6.38% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 5.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Replimune Group

Institutional investors and hedge funds have recently made changes to their positions in the business. US Bancorp DE grew its stake in shares of Replimune Group by 582.6% in the 1st quarter. US Bancorp DE now owns 4,594 shares of the company’s stock worth $45,000 after buying an additional 3,921 shares in the last quarter. BNP Paribas Financial Markets grew its stake in shares of Replimune Group by 37.5% in the 2nd quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company’s stock worth $64,000 after buying an additional 1,879 shares in the last quarter. Raymond James Financial Inc. bought a new stake in shares of Replimune Group in the 2nd quarter worth about $69,000. Tower Research Capital LLC TRC lifted its holdings in shares of Replimune Group by 2,020.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 9,692 shares of the company’s stock worth $90,000 after acquiring an additional 9,235 shares during the last quarter. Finally, AlphaQuest LLC lifted its holdings in shares of Replimune Group by 99.9% in the 2nd quarter. AlphaQuest LLC now owns 9,857 shares of the company’s stock worth $92,000 after acquiring an additional 4,925 shares during the last quarter. 92.53% of the stock is owned by hedge funds and other institutional investors.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.